Pivotal Bio Venture Partners Investment Advisor LLC Trevi Therapeutics, Inc. Transaction History
Pivotal Bio Venture Partners Investment Advisor LLC
- $106 Million
- Q2 2025
A detailed history of Pivotal Bio Venture Partners Investment Advisor LLC transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, Pivotal Bio Venture Partners Investment Advisor LLC holds 1,146,110 shares of TRVI stock, worth $11.2 Million. This represents 5.92% of its overall portfolio holdings.
Number of Shares
1,146,110Holding current value
$11.2 Million% of portfolio
5.92%Shares
1 transactions
Others Institutions Holding TRVI
# of Institutions
163Shares Held
109MCall Options Held
1.08MPut Options Held
425K-
Nea Management Company, LLC Timonium, MD13.2MShares$129 Million6.0% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.3MShares$100 Million2.96% of portfolio
-
Rubric Capital Management LP New York, NY8.53MShares$83.5 Million1.08% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.32MShares$52.1 Million0.0% of portfolio
-
Vivo Capital, LLC Palo Alto, CA4.49MShares$43.9 Million5.2% of portfolio
About Trevi Therapeutics, Inc.
- Ticker TRVI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,322,500
- Market Cap $571M
- Description
- Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...